To determine whether responses could be improved by increasing the frequency of anti-tumor CD8+ T cells, we evaluated different immunization schedules and showed that while boosting with MS-OVA could increase the frequency of CD8+ T cells, overall tumor protection in the therapeutic setting did not significantly improve compared to a single dose vaccine. The gene discussed is CD8A; the disease is neoplasm.